Efficacy of injecting platelet concentrate combined with hyaluronic acid for the treatment of vulvovaginal atrophy in postmenopausal women with history of breast cancer

PURPOSE To review critically the literature regarding effects of estrogen replacement therapy (ERT)/combined estrogen and progesterone replacement therapy (HRT) on the risk of breast cancer and on other health risks and benefits in postmenopausal women, with a focus on risks and benefits in women with a previous diagnosis of breast cancer. METHOD A literature search was conducted using Medline, Cancerline, and the bibliographies of reports published as of March 1995. All five published meta-analyses that examined the risk of breast cancer in relation to ERT/HRT in otherwise healthy women were critically reviewed. All known reports of women with a history of breast cancer given ERT/HRT subsequent to diagnosis and additional reports regarding the benefits of ERT/HRT were also reviewed. RESULTS None of the five meta-analyses demonstrated a significantly increased risk of developing breast cancer in ever users compared with never users of ERT/HRT. Current use may be associated with a small increased risk. This increased risk should be balanced by the expected benefits of ERT/HRT on quality of life, bone metabolism, and cardiovascular function. Preliminary information does not suggest a major detrimental effect of ERT/HRT in women with a previous diagnosis of breast cancer, but these reports include few women with limited follow-up data. There are no randomized trials in women with a previous diagnosis of breast cancer. CONCLUSION In healthy postmenopausal women, the benefits associated with ERT/HRT outweigh the risks. In women with a previous diagnosis of breast cancer, the balance of risks and benefits should be explored in randomized controlled trials.

Download Full-text

The effects of fractional microablative CO2 laser therapy on sexual function in postmenopausal women and women with a history of breast cancer treated with endocrine therapy

Journal of Cosmetic and Laser Therapy ◽

10.1080/14764172.2018.1481510 ◽

2018 ◽

Vol 21 (3) ◽

pp. 127-131 ◽

Cited By ~ 5

Author(s):

Paul Gittens ◽

Gregory Mullen

Keyword(s):

Breast Cancer ◽

Sexual Function ◽

Postmenopausal Women ◽

Endocrine Therapy ◽

Laser Therapy ◽

Co2 Laser ◽

History Of

Download Full-text

The Prevalence of Sarcopenic Obesity in Postmenopausal Women with a History of Breast Cancer Depending on Adopted Methodology – A Case–Control Study

Journal of Multidisciplinary Healthcare ◽

10.2147/jmdh.s274660 ◽

2020 ◽

Vol Volume 13 ◽

pp. 1749-1758

Author(s):

Emilia Kałędkiewicz ◽

Magdalena Milewska ◽

Mariusz Panczyk ◽

Dorota Szostak-Węgierek

Keyword(s):

Breast Cancer ◽

Postmenopausal Women ◽

Case Control Study ◽

Case Control ◽

Sarcopenic Obesity ◽

History Of ◽

Control Study

Download Full-text

Postmenopausal Hormone Replacement Therapy: Effect on Diagnosis and Outcome in Early-Stage Invasive Breast Cancer Treated With Conservative Surgery and Radiation

Journal of Clinical Oncology ◽

10.1200/jco.1999.17.6.1680 ◽

1999 ◽

Vol 17 (6) ◽

pp. 1680-1680 ◽

Cited By ~ 31

Author(s):

Barbara Fowble ◽

Alexandra Hanlon ◽

Gary Freedman ◽

Art Patchefsky ◽

Howard Kessler ◽

...

Keyword(s):

Breast Cancer ◽

Hormone Replacement Therapy ◽

Replacement Therapy ◽

Postmenopausal Women ◽

Cumulative Incidence ◽

Hormone Replacement ◽

Conservative Surgery ◽

Stage I ◽

Therapy Effect ◽

History Of

PURPOSE: To compare the pretreatment characteristics and outcome of postmenopausal women with stage I-II breast cancer treated with conservative surgery and radiation who had a history of hormone replacement therapy (HRT) with those who had never received HRT. MATERIALS AND METHODS: From 1979 to 1993, 485 postmenopausal women underwent excisional biopsy, axillary dissection, and radiation for stage I-II breast cancer. The median follow-up was 5.9 years. One hundred forty-one patients reported a history of HRT. The median length of use was 5 years. Three hundred forty-four patients reported no history of HRT. RESULTS: Statistically significant differences between the two groups were observed for median age (HRT 60 years v no HRT 64 years; P = .0009), median weight (HRT 142 lbs v no HRT 152 lbs; P = .004), clinical tumor size ≤ 2 cm (HRT 77% v no HRT 66%; P = .02), and the use of re-excision (HRT 62% v no HRT 49%; P = .01). The method of detection by mammogram only (HRT 52% v no HRT 42%; P = .06) was of borderline statistical significance. The HRT patients had a statistically significant increased cumulative incidence of ipsilateral breast tumor recurrence (8% v 2%; P = .02), a statistically significant decreased cumulative incidence of distant metastases (HRT 6% v no HRT 17%; P = .01), and a borderline statistically significant improvement in cause-specific survival at 10 years (HRT 92% v no HRT 86%; P = .07). Postmenopausal women with a history of HRT did not have an increased risk of contralateral breast cancer or second non–breast cancer malignancy. CONCLUSION: This study failed to identify an adverse effect of HRT on breast cancer mortality in patients with stage I-II disease treated with conservative surgery and radiation.

Download Full-text